Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK1 | P06870 | 2/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14342066 | 0.96 | F2 (0.33) | KLK1KLK5F2F10PLG | |
| Formic Acid SCHEMBL6779335 | 0.89 | KLK1 (0.36) | KLK1KLK5MAPTSMN1; SMN2 | |
| Formic Acid SCHEMBL6779721 | 0.88 | KLK1 (0.33) | KLK1KLK5 | |
| Formic Acid SCHEMBL6779717 | 0.88 | KLK1 (0.33) | KLK1KLK5 | |
| SCHEMBL6780092 | 0.85 | — | — | |
| SCHEMBL14341822 | 0.84 | NOTUM (0.34) | MAPTSMN1; SMN2 | |
| Formic Acid SCHEMBL6779916 | 0.84 | KLK1 (0.32) | KLK1KLK5F2F10PLG | |
| Formic Acid SCHEMBL6784557 | 0.84 | KLK1 (0.32) | KLK1KLK5F2F10PLG | |
| SCHEMBL14342068 | 0.83 | ALDH1A1 (0.32) | — | |
| Formic Acid SCHEMBL6780298 | 0.82 | KMT2A (0.33) | KLK1KLK5F2F10PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730697-B2 | FOR USE AS ANTIARRYTHMIC MEDICAMENTS WITH A CARDIOPROTECTIVE COMPONENT FOR PROPHYLAXIS OF AN INFARCTION AND THERAPY OF INFARCTION, AND FOR TREATMENT OF ANGINA PECTORIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-04 | — | — | US | disclosed |
| US-20030181511-A1 | Dihydrothiaphenanthrenecarbonylguanidines: composition, process of making, and use as medicament or diagnostic aid | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181511-A1 | Dihydrothiaphenanthrenecarbonylguanidines: composition, process of making, and use as medicament or diagnostic aid | TNNI3, TNNT2, TNNC1 | KLK1 4301/4885KLK5 4646/4885F2 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.